Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2011
Date:11/7/2011

e the end of the third quarter, Isis has earned an additional $5 million milestone payment from GSK for designating ISIS-AATRx as a development candidate.  Because Isis achieved this milestone in October, the Company will recognize revenue from the milestone payment in the fourth quarter of 2011.  

Operating ExpensesOn a pro forma basis, operating expenses for the three and nine months ended September 30, 2011 were $40.7 million and $111.6 million, respectively, compared to $34.6 million and $105.1 million for the same periods in 2010.   Isis' operating expenses in the first nine months of 2011 reflected moderately higher costs associated with Isis' maturing pipeline of drugs as these drugs move forward to more advanced stages of development, including into larger, longer clinical studies.
While Isis' share of mipomersen development expenses will be shared equally with Genzyme in 2012, many of the drugs in Isis' pipeline will enter later-stage clinical development.  Therefore, Isis expects the Company's operating expenses to be moderately higher next year.  

On a GAAP basis, Isis' operating expenses for the three and nine months ended September 30, 2011 were $43.0 million and $119.2 million, respectively, compared to $37.6 million and $114.6 million for the same periods in 2010.  

Net Loss Isis reported a net loss of $26.9 million and $64.8 million for the three and nine months ended September 30, 2011, respectively, compared to $12.5 million and $47.3 million for the same periods in 2010.  Basic and diluted net loss per share for the three and nine months ended September 30, 2011 was $0.27 per share and $0.65 per share, respectively, compared to $0.13 per share and $0.48 per share for the same periods in 2010.  In the first nine months of 2011 Isis' net loss increased compared to the same period in 2010 primarily due to a $20.0 million increase in Isis' net operating loss.

<
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
2. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
3. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
4. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Cambrex Reports Third Quarter 2011 Results
7. Dyadic International Reports 2011 Third Quarter Financial Results
8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
9. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
10. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
11. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
(Date:7/29/2014)... 29, 2014  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $515.2 million, or ... as detailed in Table 4, was $1.23 for the ... positioned to serve our clients with scale, alignment and innovative ... the health outcomes of our members," stated George Paz, chairman ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... 2011  TransTech Medical Solutions ( http://www.transtechmedical.com ), today announced ... for Transcription Services in the 2011 Top ... report.  TransTech has previously been ranked #3 in ... the highest overall performance score and 100% of the ...
... 2011  Today, the Consumer Healthcare Products Association (CHPA), announced Tammy ... Five Moms campaign to raise awareness of teen ... two teenage boys and a high school math teacher from ... dangers of substance abuse. Millions of Americans ...
Cached Medicine Technology:TransTech Medical Solutions Ranked #1 by KLAS for 2011 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:7/29/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer ... bridal gowns . Aside from this, it has announced that ... 68 percent off. All of its old and new clients ... sales representative says excitedly, “We are pleased to release the ... there are a lot of amazing items. It is true ...
(Date:7/29/2014)... City, MO (PRWEB) July 30, 2014 ... practices have recently been awarded the Patient-Centered Medical ... by the National Committee for Quality Assurance. Only ... achieved NCQA Level I, Level 2, or Level ... who participate in Patient-Centered Medical Home report faster ...
(Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 1Heart ... senior communities with focus on Brain Fitness Education ... in Ventura. Brain Fitness Program Director Tee Barr ... Aegis Memory Care unit and the Assisted Living ... Aegis Life Enrichment Director Christy Rozsa and Aegis ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
Breaking Medicine News(10 mins):Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Amilpar (Bovespa: AMIL3;,Bloomberg: AMIL3 BZ and APAR < GO >; ... results for the third quarter,of 2009. , ... thousand at the end of September 2009,2.7% up on 3Q08 and ... Operating Revenues totaled R$ 1,237.1 million in 3Q09, 8.4% up,year-on-year and ...
... 11 In its continuing initiatives around Doing What,s Right, ... as part of its involvement in the Clinton Global Initiative ... brings world leaders from a variety of backgrounds together to ... some of the world,s most pressing challenges. , SC ...
... sick, but elderly more likely to die , WEDNESDAY, Nov. 11 ... finds that while babies and people under the age of 40 ... death rates. , The research, published online Nov. 11 in ... in the Mexican Institute for Social Security network, who became sick ...
... published reports , WEDNESDAY, Nov. 11 (HealthDay News) -- ... company suggests that clinical data was manipulated to make ... than it actually was, thereby increasing possibilities for its ... means we,re not seeing the full picture, and the ...
... ... also desperate pioneers whose drug use had gotten the better of them every ... whether an epilepsy drug could reduce their use of cocaine. In the end, ... the final three weeks of the study with no signs of cocaine use ...
... 11 An article running in the new issue ... , "Silent Epidemic of Viral Hepatitis May Lead to ... for Congress to act on new bipartisan legislation, HR ... research, and medical management referral program for chronic hepatitis ...
Cached Medicine News:Health News:Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09 2Health News:SC Johnson Makes Commitment to Clinton Global Initiative 2Health News:SC Johnson Makes Commitment to Clinton Global Initiative 3Health News:Older People at Greater Risk of Swine Flu Death 2Health News:Trial Data on Anti-Seizure Drug Might Have Been Manipulated: Report 2Health News:Trial Data on Anti-Seizure Drug Might Have Been Manipulated: Report 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding 2
...
...
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Medicine Products: